Sign in
CompletedNo phase

RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study

Key facts

Who runs it
RxSight, Inc.
Where
Alexandria, Brecksville, Chico, Dallas, Fayetteville, Houston, Hurst, Largo, Las Vegas, Mt. Pleasant, Omaha, San Antonio, Sebring, and Sioux Falls, United StatesSee the 14 sites
Trial code
Status
Completed
People taking part
500 people enrolled
Started
3 Dec 2021
Ended
16 Dec 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Light Adjustable lens (LAL) and Light Delivery Device (LDD)
  • Control IOL
Record updated
20 April 2025

Who can take part

Age
40 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Must sign a written Informed Consent form and be willing to undergo cataract surgery for the implantation of an IOL with random assignment to either the RxSight LAL or the monofocal control IOL
  • Between the ages of 40 and 80 inclusive on the day the cataract surgery is performed
  • Willing and able to comply with the requirements for study specific procedures and visits
  • Able to complete a written questionnaire in English

Who cannot take part

  • Previous intraocular surgery in either eye. Eyes with previous pterygium excision are permitted as long as the pterygium did not extend more than 2mm onto the cornea from the limbus
  • Subjects taking systemic medication that may increase sensitivity to UV light
  • Subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen
  • Pre-existing macular disease in either eye
  • History of uveitis in either eye
  • History of ocular herpes simplex virus in either eye
  • Patients with sufficiently dense cataracts that preclude examination of the macula in either eye
  • Evidence of ectasia in either eye

Where in United States

  • Vance Thompson VisionAlexandria, United States
  • Cleveland Eye ClinicBrecksville, United States
  • Reeve Woods Eye CenterChico, United States
  • Key-Whitman Eye CenterDallas, United States
  • Vold VisionFayetteville, United States
  • Slade & Baker VisionHouston, United States
  • Texas Eye Research CenterHurst, United States
  • The Eye Institute of West FloridaLargo, United States
  • Center for SightLas Vegas, United States
  • Carolina Eyecare Physicians LLCMt. Pleasant, United States
  • Vance Thompson VisionOmaha, United States
  • Focal Point VisionSan Antonio, United States
  • Newsom EyeSebring, United States
  • Vance Thompson Vision ClinicSioux Falls, United States

About the trial

What the trial wants to find out

The primary objective of this study is to conduct a post-approval study which compares the LAL to a monofocal control IOL for safety outcomes.

The 2 groups in the trial

  • Light adjustable lens (LAL) and Light Delivery Device (LDD)Treatment being tested
  • Control IOLExisting treatment, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study
Publications
Record updated
20 April 2025